These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37627743)

  • 1. Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating
    Mori N; Hirai J; Ohashi W; Asai N; Shibata Y; Mikamo H
    Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627743
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
    Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
    J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
    Okumura H; Fukushima A; Taieb V; Shoji S; English M
    J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal therapeutic recommendation for Clostridioides difficile infection in pediatric and adolescent populations: a systematic review and meta-analysis.
    Tashiro S; Mihara T; Okawa R; Tanaka Y; Samura M; Enoki Y; Taguchi K; Matsumoto K; Yamagishi Y
    Eur J Pediatr; 2023 Jun; 182(6):2673-2681. PubMed ID: 37000258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Efficacy of Therapeutic Agents for Clostridioides difficile Infection Based on Four Severity Classifications.
    Ohtani M; Yoshizawa S; Miyazaki T; Kumade E; Hirayama S; Sakamoto M; Murakami H; Maeda T; Ishii Y; Matsumoto T; Tateda K
    Jpn J Infect Dis; 2024 Sep; 77(5):281-284. PubMed ID: 38556300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of
    Hernando-Gozalo M; Rescalvo-Casas C; Seijas-Pereda L; Cuadros-González J; Pérez-Tanoira R
    Heliyon; 2024 May; 10(10):e30742. PubMed ID: 38803946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials.
    Igarashi Y; Tashiro S; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
    J Infect Chemother; 2018 Nov; 24(11):907-914. PubMed ID: 30170735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective study of the efficacy and safety of metronidazole and vancomycin for Clostridioides difficile infection.
    Misawa K; Iketani O; Enoki Y; Taguchi K; Uno S; Uwamino Y; Hasegawa N; Matsumoto K
    J Infect Chemother; 2021 Oct; 27(10):1407-1412. PubMed ID: 34023223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
    Tashiro S; Taguchi K; Enoki Y; Matsumoto K
    Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective budget impact analysis of fidaxomicin treatment for
    Siefen AC; Kurte MS; Bauer AM; Cornely OA; Wingen-Heimann S; Kron F
    Expert Rev Pharmacoecon Outcomes Res; 2024 Oct; 24(8):933-942. PubMed ID: 38712561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection.
    Whitney L; Nesnas J; Planche T
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin versus oral vancomycin for
    Pettit NN; Lew AK; Nguyen CT; Bell E; Lehmann CJ; Pisano J
    Infect Control Hosp Epidemiol; 2024 Oct; 45(11):1-7. PubMed ID: 39363592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection.
    Diaz-Pollan B; Carrasco Molina S; Marcelo C; de Gea Grela A; Martínez-Martín P; Jiménez-González M; Moreno Ramos F; Mora-Rillo M
    Cureus; 2023 Nov; 15(11):e48735. PubMed ID: 38094526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of
    Dubberke ER; Gerding DN; Kelly CP; Garey KW; Rahav G; Mosley A; Tipping R; Dorr MB
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa157. PubMed ID: 32523972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of fidaxomicin in patients at high risk of
    Colwell B; Aguilar J; Hughes F; Goriacko P; Chen V; Chang M; Bartash R; Guo Y
    Antimicrob Steward Healthc Epidemiol; 2024; 4(1):e127. PubMed ID: 39290625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
    Kimura T; Stanhope S; Sugitani T
    J Infect Chemother; 2020 May; 26(5):438-443. PubMed ID: 32081648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.